Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Publikáció
TIM3 Blockade with Hypomethylating Therapy Restores NK Cell and Cytotoxic CD4+ T-cell Activity in Patients with AML or MDS.
2026. nov. 3.· Cancer immunology research· PUBMED
Publikáció
TIM-3 Up-regulation Is Associated With Altered Cytotoxic Function of Allogeneic Vγ9Vδ2 T Cells in Urinary Bladder Cancer.
2026. nov. 1.· Anticancer research· PUBMED
Publikáció
TIM-3 Functions as an Activator of NK Cells in GBM and Can Be Upregulated by Torin-1: Implications for Exogenous NK Cell Transplantation.
2026. okt. 23.· Immunology· PUBMED
Publikáció
Disruption of ACTG1 potentiates anti-TIM-3 immunotherapy by reprogramming the immunosuppressive microenvironment via the CSF3/CSF3R axis in pancreatic cancer.
2026. okt. 14.· Frontiers in immunology· PUBMED
Publikáció
Soluble TIM-3 and galectin-9 in cerebrospinal fluid are associated with disability at 6 months in aquaporin-4 IgG-positive neuromyelitis optica spectrum disorder.
2026. okt. 5.· Frontiers in immunology· PUBMED
Publikáció
Low-dose antiangiogenic multikinase inhibitor AL3810 synergizes with PD-1 blockade by reducing CSF1-driven MHC-IIint tumour-associated macrophages to optimize TIM-3+ CD8+ T-cell effector function.
2026. szept. 28.· British journal of pharmacology· PUBMED
Publikáció
Serine protease inhibitor from Trichinella spiralis ameliorates diet-induced obesity and adipose tissue inflammation through TIM-3-dependent macrophage reprogramming.
2026. szept. 25.· PLoS pathogens· PUBMED
Publikáció
Lnc-TIM3 promotes acute lymphoblastic leukemia progression through miR-5094-mediated regulation of TIM3.
2026. aug. 28.· Translational cancer research· PUBMED
Publikáció
TIM-3 as a therapeutic target in anaplastic thyroid carcinoma: Preclinical and transcriptomic evidence supporting a new immunotherapy avenue.
2026. aug. 28.· Clinical immunology (Orlando, Fla.)· PUBMED
Publikáció
Association of serum TIM-3 and Galectin-9 levels with glaucoma progression: implications for clinical monitoring.
2026. aug. 15.· American journal of translational research· PUBMED
Publikáció
TIM3-targeted delivery of venetoclax overcomes drug resistance and reinvigorates NK cell activity in acute myeloid leukemia.
2026. aug. 12.· Nature cancer· PUBMED
Publikáció
TIM3 as a therapeutic target in anaplastic thyroid cancer: upregulation in M2-like macrophages induced by tumor microenvironment-derived TGFβ1.
2026. aug. 5.· The Journal of pathology· PUBMED
Publikáció
NKG2A-HLA-E and TIM3-galectin 9 pathways promote immune inhibition and represent therapeutic vulnerabilities in pancreatic ductal adenocarcinoma.
2026. júl. 3.· Cancer immunology, immunotherapy : CII· PUBMED
Publikáció
The significance of galectin-9 and T-cell immunoglobulin and mucin domain-containing molecule-3 (TIM-3) in patients with chronic lymphocytic leukemia: The role of immune evasion.
2026. júl. 2.· Human immunology· PUBMED
Publikáció
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.
2026. jún. 19.· Journal for immunotherapy of cancer· PUBMED
Publikáció
TIM-3 as an immune and leukemia stem-cell biomarker in acute myeloid leukemia: diagnostic laboratory and translational perspectives.
2026. jún. 17.· Clinica chimica acta; international journal of clinical chemistry· PUBMED
Publikáció
PRDM1 Drives a TIM3+ Macrophage Immunosuppressive Niche via LGALS9 Signaling in Prostate Cancer Progression.
2026. jún. 16.· Oncology research· PUBMED
Publikáció
Assessment of CTLA-4, LAG-3, and TIM-3 Expression in Pediatric Patients With β-Thalassemia Major and Their Association With Alloimmunization.
2026. jún. 7.· Transfusion medicine reviews· PUBMED
Publikáció
The expression status and clinical value of TIM-3 in intrahepatic cholangiocarcinoma.
2026. jún. 5.· BMC cancer· PUBMED
Publikáció
The Signaling Networks of TIM-3, TGF-β, and STING in Glioblastoma.
2026. máj. 28.· Cells· PUBMED
Publikáció
The implications of TMSB4X in TIM3 hypermethylation and CD8+ T cell exhaustion in diffuse large B-cell lymphoma.
2026. máj. 23.· Scientific reports· PUBMED
Publikáció
TIM-3 in AML: a janus-faced orchestrator of immune exhaustion and leukemic self-renewal.
2026. máj. 19.· Cancer cell international· PUBMED
Publikáció
TIM-3-dependent lysosome biogenesis is required for myelin debris clearance in macrophages.
2026. máj. 12.· Brain : a journal of neurology· PUBMED
Preprint
TIM3 + Tumor Associated M2 Macrophages Impair Antitumor T Cell Immunity and Promote Gastric Cancer Progression and Peritoneal Metastasis.
2026. ápr. 17.· bioRxiv : the preprint server for biology· PUBMED
Publikáció
Radiation-induced MYB reduction unleashes TIM-3 expression in NK cells to attenuate antitumor immunity in colorectal cancer.
2026. ápr. 10.· Journal of translational medicine· PUBMED
Publikáció
Anti-TIM-3 antibody TQB2618 in combination with penpulimab in relapsed or refractory classic Hodgkin lymphoma previously treated with PD-1/PD-L1 therapy: a multicenter, open-label, single-arm, phase Ib clinical trial.
2026. ápr. 10.· Journal for immunotherapy of cancer· PUBMED
Publikáció
Soluble TIM-3 and galectin-9 serve as additional diagnostic biomarkers in primary central nervous system lymphoma.
2026. ápr. 2.· Journal of neurology· PUBMED
Publikáció
TIM-3 in AML: pathogenic roles and therapeutic targetability.
2026. ápr. 2.· Clinical and experimental medicine· PUBMED
Publikáció
Regulatory Effect of Moxibustion on Macrophage Polarization and Migration in RA Model Rats and the Role of TIM-3.
2026. márc. 27.· Journal of visualized experiments : JoVE· PUBMED
Publikáció
Increased LAG-3, TIM-3, and IDO1 Expression Is Associated With Oral Squamous Cell Carcinoma in Never Smokers and Never Drinkers.
2026. márc. 19.· Oral diseases· PUBMED